anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators will study acupuncture in a pilot, randomized controlled trial (RCT) in the emergency department (ED) of a large, tertiary care hospital, Abbott Northwestern Hospital (ANW). The investigators suggest that the proposed intervention - provision of acupuncture in the ED as an alternative to usual ED care - will reduce pain and interrupt the trajectory (and potential cycle) of medication misuse by providing an alternative at a critical point of contact within the healthcare system, potentially disrupting the pathway from ED visit to opioid usage after discharge. In this study, the investigators will assess the feasibility of implementation, practicality, and expansion of an acupuncture RCT in the ED environment. The study will prospectively measure and analyze change in pain intensity after treatment with acupuncture or usual care, use of opioids during ED visit, prescriptions written for opioids at ED discharge, and use of opioids at 30-day follow-up.

Study data will be collected using electronic health record (EHR) data and patient-reported outcomes. Patient-reported outcomes will be collected via an electronic database and solely for research purposes. The acupuncture intervention provided in the ED will be provided at no cost to the patient and will be paid for by the study sponsor. The practice of providing acupuncture in ANW's ED at no charge to the patient has been in place since November 2013. In conducting this pilot study, it will assess the ability to implement and carry out a RCT of acupuncture in the ED. By comparing pain change and opioid utilization among patients who receive acupuncture versus those who receive usual emergency department care, and by conducting follow-up data collection, the investigators will be able to better understand the potential role of a common non-pharmacological pain management strategy for mitigating pain and reducing opioid use in the emergency medicine setting.
The present invention relates to a novel Cardiac And Pancreatic Protein (CAPP) which is a member of the muscle derived growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human CAPP protein. CAPP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CAPP activity. Also provided are diagnostic methods for detecting the presence of activated T-cells, and mature heart, pancreas and placental tissues and cells. The CAPP polypeptides can also be employed in cell culture media for regulating cell differentiation and maintaining heart, placenta and pancreas cells.
An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials. An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials. A method, apparatus and computer usable program code for identifying regions in the ground at a well site (200). Continuous data (902) is received from the well site (200); reducing redundancies in the continuous data (902) received from the well site (200) to form processed data. Cluster analysis is performed (2308) using the processed data to form a set of cluster units, wherein the set of cluster units (1402) include different types of cluster units that identify differences between regions in the ground at the well site (200). Properties are identified for each type of cluster unit in the set of cluster units (1400) to form a model for the well site (200).
1- Suffering of some diabetic patients from complication of diabetes. 2- The real Causes of cadiac diseases and other disorders in diabetic patients. 3- Importance of addition of some elements as effective substance to drugs used in diabetes treatment to protect diabetic patients from complications of diabetes. 4- Co-enzymeQ 10 is a giant step in nutritional science protects patient from heart muscale weakness and other diseases due to having diabetes. 5- Diabetes damages some essential elements important for enzymes formation and essential amino acid production and its lack leads to appearance of many psychic and somatic symptoms. 6. The solution is addition of; - Vit.BÌ 75mg - Vit.B12 150mcg - Folic Acid 200 meg -Vit.C 80 mg -Vit.E 200 mg - Co-enzymeQ 10 30mg To drugs used to lower the blood sugare level as a protection and prophylaxis for diabetic patients.
BACKGROUND: Severe bacterial infections can trigger acute lung injury (ALI) and acute respiratory distress syndrome, with bacterial pathogen-associated molecular patterns (PAMPs) exacerbating the inflammatory response, particularly in COVID-19 patients. Cyclic-di-GMP (CDG), one of the PAMPs, is synthesized by various Gram-positve and Gram-negative bacteria. Previous studies mainly focused on the inflammatory responses triggered by intracellular bacteria-released CDG. However, how extracellular CDG, which is released by bacterial autolysis or rupture, activates the inflammatory response remains unclear.
METHODS: The interaction between extracellular CDG and myeloid differentiation protein 2 (MD2) was investigated using in vivo and in vitro models. MD2 blockade was achieved using specific inhibitor and genetic knockout mice. Site-directed mutagenesis, co-immunoprecipitation, SPR and Bis-ANS displacement assays were used to identify the potential binding sites of MD2 on CDG.
RESULTS: Our data show that extracellular CDG directly interacts with MD2, leading to activation of the TLR4 signalling pathway and lung injury. Specific inhibitors or genetic knockout of MD2 in mice significantly alleviated CDG-induced lung injury. Moreover, isoleucine residues at positions 80 and 94, along with phenylalanine at position 121, are essential for the binding of MD2 to CDG.
CONCLUSION: These results reveal that extracellular CDG induces lung injury through direct interaction with MD2 and activation of the TLR4 signalling pathway, providing valuable insights into bacteria-induced ALI mechanisms and new therapeutic approaches for the treatment of bacterial co-infection in COVID-19 patients.
Irbesartan: No data are available in regard to overdosage in humans. However, daily doses of 900 mg for 8 weeks were well tolerated. The most likely manifestations of overdosage are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. Irbesartan is not removed by hemodialysis.

To obtain up-to-date information about the treatment of overdosage, a good resource is a certified regional Poison Control Center. Telephone numbers of certified Poison Control Centers are listed in the Physicians’ Desk Reference (PDR). In managing overdose, consider the possibilities of multiple-drug interactions, drug-drug interactions, and unusual drug kinetics in the patient.

Laboratory determinations of serum levels of irbesartan are not widely available, and such determinations have, in any event, no established role in the management of irbesartan overdose.

Acute oral toxicity studies with irbesartan in mice and rats indicated acute lethal doses were in excess of 2000 mg/kg, about 25- and 50-fold the MRHD (300 mg) on a mg/m2 basis, respectively.

Hydrochlorothiazide: The most common signs and symptoms of overdose observed in humans are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.
The invention relates to a Chinese medicinal composition for treatment of edema and ophthalmia and a preparation method thereof. The Chinese medicinal composition is characterized by having the efficacy of clearing away heat and toxic materials, resisting inflammation, inducing diuresis and reducing edema, dispelling wind and removing obstruction in meridians, stopping bleeding, invigorating blood circulation and alleviating pain, etc., and can eliminate edema symptom proteinuria, hematuria, erythrocyte cylindruria, dropsy, high blood pressure, inflammation and the like. The matrix is prepared from the following Chinese medicinal composition and pharmaceutical excipients by weight: 1-50 parts of Scutellaria baicalensis, 1-100 parts of Stephania longa, 1-50 parts of acorus gramineus, and 1-50 parts of Pseudo-ginseng. The composition of the invention cares the whole of human body, prevents complications, treats both symptoms and root causes, has no toxic or side effect, and also has significant curative effect on some symptoms on which western medicines are non-effective. The composition provided by the invention is applied to clinical treatment of 12 edema cases, wherein the minimum age is 6 years old, the maximum age is 48 years old, the shortest disease course is 5 days, the longest disease course is 3 months, and all the cases are cured. The composition is applied to treatment of 26 ophthalmia cases, wherein the minimum age is 4 years old, the maximum age is 56 years old, the shortest disease course is 1 day, the longest disease course is 15 days, and all the cases are cured.
Aspects of the present invention describe a method and apparatus for viewing and interfacing with gene expression on a computer device. A computer based device interfaces with gene the expression data by representing a plate having one or more wells and their contents with a matrix of elements addressable along at least two-dimensions. Each of the elements in the matrix are processed and then distinguished based upon their passing and failing one or more metrics for gene expression data. The interface displays those values associated with the distinguished elements in the matrix using colors, shapes and symbols. Depending on the results, some of the elements in the matrix may be flagged and then filtered from the data set. Remaining gene expression values not filtered from the matrix of elements are displayed and processed further.
After the laparoscopic surgery was completed, the trocar incision sites were closed. Following the infiltration rules, local anesthetic (15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine) was applied to the trocar sites of skin, fascia, muscle, and preperitoneal area by the surgical team after the operation. A total of 20 mL of local anesthetic was used, with 6 mL for trocar sites of 10 mm, and 4 mL for trocar sites of 5 mm .Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
OBJECTIVE: Early detection and effective management of hearing loss constitute the key to improving the quality of life of individuals with hearing loss. However, in standardized pure tone audiometry, it is sometimes difficult for elderly patients to understand and follow all instructions. Audiologists also require time, expertise, and patience to ensure that an elderly can identify the faintest levels of stimuli during a hearing test. Therefore, this study aimed to devise and validate a formula to predict the pure tone threshold at each frequency across 0.5-4 kHz (PTTs) using speech reception threshold.
METHODS: The 1226 audiograms of hearing-impaired individuals aged 60-90 years were reviewed. The random sample function randomly assigned 613 participants to the training and testing sets each. A linear model was created to predict the PTT value at each frequency based on variables significant at all frequencies across 0.5-4 kHz. The adjusted-R2 value was considered to indicate the performance of the predictive model. Pearson's correlation coefficient was used to describe the relationship between the actual and predicted PTT at 0.5, 1, 2, and 4 kHz among the testing set to measure the performance of the proposed model.
RESULTS: The predictive model was devised using variables based on the speech recognition threshold (SRT) after adjusting with age in the training set. The overall prediction accuracy demonstrated a higher adjusted-R2 ranging from 0.74 to 0.89 at frequencies of 0.5, 1, and 2 kHz, whereas a low percentage of explained variance was observed at 4 kHz (adjusted-R2 = 0.41). This predictive model can serve as an adjunctive clinical tool for guiding determination of the PTTs. Moreover, the predicted PTTs can be applied in the hearing aid programming software to set appropriate hearing aid gain using standard prescriptive formulas.
The GP681 in this test is a prodrug of a polymerase acidic protein (PA, Polymerase Acidic protein) inhibitor. Its metabolite GP1707D07 can selectively inhibit the cap-dependent endonuclease of influenza virus and prevent influenza virus replication. Mechanism of action against influenza virus. The results of previous non-clinical studies show that GP681 can effectively inhibit influenza virus replication, has good safety, and has antiviral activity 1,000 times that of oseltamivir phosphate. It also has good antiviral activity against oseltamivir resistant strains. And it is expected to have a longer half-life than oseltamivir phosphate. Therefore, it is expected that a new type of PA inhibitor can be developed to provide patients with influenza with a new mechanism of action, better efficacy, and higher compliance.
The study is an open-label, single-arm, single-center, Phase II clinical trial. The trial design adopts the Simon optimal two-stage design. The number of effective cases in the first stage is 15; if fewer than 5 effective cases are observed, the trial will be terminated, otherwise, the trial will continue. The total sample size for the trial is at least 43 cases. All subjects receive treatment with the Toripalimab and Chidamide regimen until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions occur, or treatment is terminated for other reasons, whichever comes first. After the end of treatment, subjects are required to complete the end-of-treatment visit within 7 days. Safety follow-up after the last dose is required at 30 days (±7 days) and 90 days (±7 days) after the last dose, with adverse event (AE) collection up to 90 days after the last dose. After the end of dosing, subjects enter the follow-up period with a telephone follow-up every 12 weeks (±7 days) to collect survival information and subsequent anti-tumor treatments until death or loss to follow-up. If a subject discontinues treatment for reasons other than PD (progressive disease), efficacy evaluation should continue at the same frequency as during the dosing period until the subject experiences PD, starts a new anti-tumor treatment, dies, or is lost to follow-up.

Treatment should be continued as long as clinical benefit is observed, until the patient is no longer tolerating it, for a maximum of 2 years of treatment. Atypical responses may be observed (for example, a temporary increase in tumor size or the appearance of new small lesions within the first few months, followed by a reduction in tumor size). If the patient's clinical symptoms are stable or continue to improve, even with preliminary evidence of disease progression, based on the overall judgment of clinical benefit, it may be considered to continue treatment with this regimen until disease progression is confirmed.
Systems and methods for providing remote access to a cinematic production. A server may generate and cache frames for a cinematic production while creating frame descriptors that are placed in the catalogue. A synchronization process synchronizes the catalogue with one or more clients. Using the catalogue, the client is able to select desired frames for viewing before frames are received at the client from the server. The server may receive a request for frames from the client, where the request includes an identifier component of the frame descriptor in the catalogue. The requested frames are returned by the server to the client for display at the client.
Prospective benchmarking of an observational analysis against a randomized trial increases confidence in the benchmarking process as it relies exclusively on aligning the protocol of the trial and the observational analysis, while the trials findings are unavailable. The Randomized Evaluation of Decreased Usage of Betablockers After Myocardial Infarction (REDUCE-AMI, ClinicalTrials.gov ID: NCT03278509) trial started recruitment in September 2017 and results are expected in 2024. REDUCE-AMI aimed to estimate the effect of long-term use of beta blockers on the risk of death and myocardial following a myocardial infarction with preserved left ventricular systolic ejection fraction. We specified the protocol of a target trial as similar as possible to that of REDUCE-AMI, then emulated the target trial using observational data from Swedish healthcare registries. Had everyone followed the treatment strategy as specified in the target trial protocol, the observational analysis estimated a reduction in the 5-year risk of death or myocardial infarction of 0.8 percentage points for beta blockers compared with no beta blockers; effects ranging from an absolute reduction of 4.5 percentage points to an increase of 2.8 percentage points in the risk of death or myocardial infarction were compatible with our data under conventional statistical criteria. Once results of REDUCE-AMI are published, we will compare the results of our observational analysis against those from the trial. If this prospective benchmarking is successful, it supports the credibility of additional analyses using these observational data, which can rapidly deliver answers to questions that could not be answered by the initial trial. If benchmarking proves unsuccessful, we will conduct a "postmortem" analysis to identify the reasons for the discrepancy. Prospective benchmarking shifts the investigator focus away from an endeavour to use observational data to obtain similar results as a completed randomized trial, to a systematic attempt to align the design and analysis of the trial and the observational analysis.
Participant receives prednisolone.placebo and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone-placebo for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon-placebo: One capsule every morning.
Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with triclocarban soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The triclocarban forearm will be swabbed at baseline and 6 hours.
Tumors are staged according to the criteria of the Union for International Cancer Control (UICC). Tumor volume was determined by mammography or magnetic resonance imaging (MRI). Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
This is a cohort of 15 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after having an EEG for possible seizures, but found to have a normal EEG. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after birth.
The overarching goal of this pilot project is to elucidate factors that influence families' engagement in indicated prevention/early intervention programming for youth conduct problems. We will explore factors previously shown to influence engagement, including parent motivational cognitions, family context variables, and preferences for intervention type. Study aims are organized around a randomized preference trial with a parallel hybrid design structure (see Abikoff, 2001). Families with youth ages 5-12, referred to community mental health clinics in Michigan, will be invited to participate in a prevention study. Families who chose to participate were assigned at random to preference (i.e. choice) or no preference (i.e. no choice) conditions. Those randomly assigned to the preference condition were allowed to choose between four intervention options: clinic-based services-as-usual (youth intervention); individual, home-based Oregon Parent Management Training (PMTO; Patterson, 2005), individual, clinic-based PMTO, and in-person group-based PMTO (Parenting Through Change; Forgatch \& DeGarmo, 1999). Families in the no-choice condition were randomly assigned to one of the same four conditions.
Embodiments of the present disclosure pertain to anti-viral compounds suitable for use in blocking virus entry into cells. Further embodiments of the present disclosure pertain to methods of blocking virus entry into cells by associating the cells with at least one anti-viral compound of the present disclosure. In some embodiments, the associating occurs in vitro. In some embodiments, the associating occurs in vivo in a subject through administration of the at least one anti-viral compound to the subject. Additional embodiments of the present disclosure pertain to methods of treating or preventing a viral infection in a subject by administering to the subject at least one anti-viral compound of the present disclosure. In some embodiments, the subject is a human being suffering from or vulnerable to the viral infection. In some embodiments, the virus includes a coronavirus, such as severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2).
In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.